Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Depreciation & Amortization (CF): 2018-2024

Historic Depreciation & Amortization (CF) for Stoke Therapeutics (STOK) over the last 7 years, with Dec 2024 value amounting to $2.2 million.

  • Stoke Therapeutics' Depreciation & Amortization (CF) fell 18.15% to $442,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year decrease of 17.00%. This contributed to the annual value of $2.2 million for FY2024, which is 12.00% down from last year.
  • As of FY2024, Stoke Therapeutics' Depreciation & Amortization (CF) stood at $2.2 million, which was down 12.00% from $2.5 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Depreciation & Amortization (CF) registered a high of $2.5 million during FY2023, and its lowest value of $900,000 during FY2020.
  • For the 3-year period, Stoke Therapeutics' Depreciation & Amortization (CF) averaged around $2.1 million, with its median value being $2.2 million (2024).
  • As far as peak fluctuations go, Stoke Therapeutics' Depreciation & Amortization (CF) soared by 100.00% in 2020, and later decreased by 12.00% in 2024.
  • Stoke Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $900,000 in 2020, then climbed by 11.11% to $1.0 million in 2021, then surged by 54.60% to $1.5 million in 2022, then spiked by 61.71% to $2.5 million in 2023, then decreased by 12.00% to $2.2 million in 2024.